Skip to main content
CDC Website

HIV

EHE Plans and Websites

To achieve the goal of reducing new HIV infections in the United States by 75% by 2025 and 90% by 2030, health departments and community partners are working collaboratively to develop and implement plans to End the HIV Epidemic (EHE). The planning process includes engagement of the community, HIV planning bodies, HIV prevention and care providers, and other partners in aligning resources and activities to develop jurisdictional EHE plans.

HIV Prevention and Alcohol (R34 Clinical Trials Optional)

The FOA seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research.

The US HIV Prevention and Alcohol (R01 Clinical Trials Optional)

The FOA seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research.

HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)

The goals of this program are to support locally relevant research in critical areas of HIV-associated non-communicable diseases (NCDs) at Low- and Middle-Income Country (LMIC) Institutions, to enhance research capacity, and build a network of researchers both within and across LMICs to address this critical burden.

Oral Health for People With HIV

This webpage discusses how good oral health is an important part of managing HIV and your overall health. With the right treatment, your mouth can feel better. That is a big step toward living well with HIV.

What is Harm Reduction?

This video is part of the NIDA series At the Intersection: Stories of Research, Compassion, and HIV Services for People who Use Drugs.“Harm reduction” is defined as interventions aimed to help people avoid the negative effects of drug use by meeting people where they are with kindness and respect. In this video, viewers hear from people who use drugs, people who are in recovery from drug use, and harm reduction professionals on what harm reduction is (and isn’t) in their own words.

Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support applications for epidemiological and observational research projects on the long-term cardiopulmonary sequelae following treatment for tuberculosis (TB). Investigators should propose additional testing and data collection in existing cohorts of adult and/or pediatric TB participants to better characterize and understand adverse outcomes and morbidity associated with TB disease post treatment in individuals with and without HIV infection.

TelePrEP Online Learning Series

This TelePrEP Online Learning Series provides information and resources to health departments, community-based organizations, and community health centers wanting to expand, strengthen, or develop a telePrEP program.